• Publications
  • Influence
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
BACKGROUND Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. ThisExpand
  • 5,135
  • 251
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity inExpand
  • 4,359
  • 191
  • PDF
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
PURPOSE Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, improves survival when combined with carboplatin/paclitaxel for advanced nonsquamous non-small-cell lungExpand
  • 1,367
  • 95
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
BACKGROUND First‐line therapy for advanced non–small‐cell lung cancer (NSCLC) that lacks targetable mutations is platinum‐based chemotherapy. Among patients with a tumor proportion score forExpand
  • 1,861
  • 78
  • PDF
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
S. Novello1, F. Barlesi2, R. Califano3,4, T. Cufer5, S. Ekman6, M. Giaj Levra7, K. Kerr8, S. Popat9, M. Reck10, S. Senan11, G. V. Simo12, J. Vansteenkiste13 & S. Peters14 on behalf of the ESMOExpand
  • 1,307
  • 69
  • PDF
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
BACKGROUND The cancer‐cell–killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor–mediated immunosuppression with bevacizumab. This open‐label, phase 3Expand
  • 1,115
  • 64
  • PDF
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
BACKGROUND Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small‐cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potentialExpand
  • 1,313
  • 62
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
BACKGROUND An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression‐free survival, as compared with placebo, among patients with stage III, unresectableExpand
  • 839
  • 47
First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer
BACKGROUND Enhancing tumor‐specific T‐cell immunity by inhibiting programmed death ligand 1 (PD‐L1)–programmed death 1 (PD‐1) signaling has shown promise in the treatment of extensive‐stageExpand
  • 722
  • 41
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
S. Peters1, A.A. Adjei2, C. Gridelli3, M. Reck4, K. Kerr5 & E. Felip6 on behalf of the ESMO Guidelines Working Group* Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland;Expand
  • 615
  • 35